Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other financing activities (2021 - 2025)

Cytek Biosciences (CTKB) has disclosed Other financing activities for 5 consecutive years, with $268000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 106.15% year-over-year to $268000.0, compared with a TTM value of $670000.0 through Dec 2025, up 20.94%, and an annual FY2025 reading of $670000.0, up 20.94% over the prior year.
  • Other financing activities was $268000.0 for Q4 2025 at Cytek Biosciences, up from $171000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $268000.0 in Q4 2025 and bottomed at -$1.1 million in Q3 2021.
  • Average Other financing activities over 5 years is $48187.5, with a median of $120000.0 recorded in 2023.
  • The sharpest move saw Other financing activities soared 159.65% in 2024, then decreased 21.54% in 2025.
  • Year by year, Other financing activities stood at -$1.1 million in 2021, then soared by 106.57% to $71000.0 in 2022, then skyrocketed by 43.66% to $102000.0 in 2023, then grew by 27.45% to $130000.0 in 2024, then surged by 106.15% to $268000.0 in 2025.
  • Business Quant data shows Other financing activities for CTKB at $268000.0 in Q4 2025, $171000.0 in Q3 2025, and $102000.0 in Q2 2025.